Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Max Founder Analjit to...

    Max Founder Analjit to infuse Rs 300 cr in Max India in lieu of warrants

    Written by Ruby Khatun Khatun Published On 2017-05-12T12:43:39+05:30  |  Updated On 12 May 2017 12:43 PM IST
    Max Founder Analjit to infuse Rs 300 cr in Max India in lieu of warrants


    New Delhi: Max India Limited (Max India) announced that it will raise funds from its Sponsor, Max Group’s Founder and Chairman Emeritus Mr. Analjit Singh, by issuing warrants amounting to Rs. 300 crore at Rs. 154.76 per share of Max India, priced in accordance with SEBI guidelines.


    The total number of warrants issued will be 1,93,84,854 which translates to approx. 4% stake in the company for the Sponsors.







    The Sponsors’ shareholding in the Company will increase to 45.12% as a result of this transaction.


    A significant portion of the proceeds from this transaction will be utilized by Max India to acquire a 3.75% stake in its flagship business Max Healthcare (MHC) from International Finance Corporation (IFC), which owns a 7.5% stake in the latter company. IFC’s balance 3.75% stake in MHC will be acquired by Max India’s joint venture partner in MHC – the Life Healthcare Group, which is South Africa’s second largest hospital chain. The total consideration for the stake acquisition will be Rs. 423 crore, translating to Rs. 105 per share of MHC.


    IFC has been a long-standing investor in MHC, who acquired stakes in multiple tranches over a period of 10 years. Post acquisition, both JV partners’ stake in MHC will increase to 49.7% each.

    Mr. Rahul Khosla, President, Max Group, Chairman, Max India and Chairman Max Healthcare, said, “Max India’s stake increase in Max Healthcare reflects our confidence in the company’s potential. We remain committed to providing the capital the business needs to continue on its growth trajectory. Max Healthcare’s key specialities, including Neurosciences, Oncology, Cardiac and Renal Sciences continue to report strong growth, and we are excited about the growth potential from our new growth initiatives, such as Oncology Day Care, Digicare and Max Labs. In addition, we have significant headroom for growth as we build out new capacity at Max Smart Super Speciality Hospital, Saket, Max Vaishali and several other existing locations.”

    Commenting on the Sponsors’ stake increase, Mr. Mohit Talwar, Managing Director, Max India said, “The increase in the Sponsors’ shareholding represents their unyielding commitment to the company, and more specifically, their confidence in the immense growth prospects of the underlying healthcare, health insurance and senior living businesses. IFC has been a critical supporter through MHC’s journey over the past decade and we hope to partner with them again soon.”

    Mr. Andre Meyer, CEO, Life Healthcare said, “The increase in shareholding reflects Life Healthcare’s continued commitment to the Indian healthcare market and a furthering of the partnership with Max India.”

    Max Healthcare, Max India’s flagship operating company, reported 23% growth in Gross Revenues to Rs. 1,939 Cr. in first 9 months, while its EBITDA grew 34% to Rs. 203 Cr. over the corresponding period last year. During 9M FY2017, a significant proportion of revenue contributions came from MHC’s major specialities.


    Cardiac SciencesDigicareIFCInternational Finance CorporationLife HealthcareMax GroupMax HealthcareMax IndiaMax India LimitedMax LabsMax Smart Super Speciality HospitalMHCMr. Analjit SinghMr. Andre MeyerMr. Mohit TalwarMr. Rahul KhoslaNeurosciencesoncologyOncology Day Careraise fundsRenal SciencesRs. 154.76 per shareRs. 300 croreSEBI
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok